Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MDGL Madrigal Pharmaceuticals, Inc.

交易中 11-22 15:55:46 EST

346.67

+17.43

+5.29%

最高351.07	最低323.72	成交量45.38万
今开323.72	昨收329.24	日振幅8.31%
总市值75.61亿	流通市值36.37亿	总股本2,181万
成交额1.56亿	换手率4.33%	流通股本1,049万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals, Inc.","latestPrice":346.665,"timestamp":1732308945445,"preClose":329.24,"halted":0,"volume":453820,"delay":0,"floatShares":10490253,"shares":21810407,"eps":-25.017162,"marketStatus":"交易中","marketStatusCode":2,"change":17.425,"latestTime":"11-22 15:55:46 EST","open":323.72,"high":351.065,"low":323.72,"amount":156172427.6374,"amplitude":0.083055,"askPrice":347.08,"askSize":258,"bidPrice":346.25,"bidSize":285,"shortable":3,"etf":0,"ttmEps":-25.017162,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"adjPreClose":329.24,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":325.3,"preClose":329.24,"latestTime":"09:28 EST","volume":321,"amount":104611.66584,"timestamp":1732285680093},"postHourTrading":{"tag":"盘后","latestPrice":329.24,"preClose":329.24,"latestTime":"19:41 EST","volume":2652,"amount":873061.67,"timestamp":1732236107666},"volumeRatio":0.900765,"impliedVol":0.5736,"impliedVolPercentile":0.3611},"requestUrl":"/m/hq/s/MDGL","defaultTab":"news","newsList":[{"id":"2485930162","title":"Madrigal Pharmaceuticals, Inc.盘中异动 临近午盘股价大涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485930162","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485930162?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:30","pubTimestamp":1732293008,"startTime":"0","endTime":"0","summary":"北京时间2024年11月23日00时30分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.25%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.67%。其相关个股中，Apollomics Inc C/Wts 01/04/2028 、Replimune Group, Inc.、Exicure, Inc.涨幅较大，Virpax Pharmaceuticals, Inc.、Exicure, Inc.、Molecular Templates, Inc.较为活跃，换手率分别为1774.14%、125.02%、90.62%，振幅较大的相关个股有Apollomics Inc C/Wts 01/04/2028 、Virpax Pharmaceuticals, Inc.、Exicure, Inc.，振幅分别为63.64%、62.35%、45.86%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112300300898e44326&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112300300898e44326&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2484924308","title":"Madrigal Pharmaceuticals, Inc.盘中异动 急速上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484924308?lang=zh_cn&edition=full","pubTime":"2024-11-19 23:58","pubTimestamp":1732031921,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日23时58分，Madrigal Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.03%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，Psyence Biomedical Ltd C/Wts 25/01/2029、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Dermata Therapeutics Inc C/Wts 涨幅较大，Tff Pharmaceuticals, Inc.、Exicure, Inc.、Hcw Biologics Inc.较为活跃，换手率分别为797.17%、117.89%、106.06%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为81.67%、62.18%、52.14%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119235841971a77a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119235841971a77a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","MDGL","BK4588"],"gpt_icon":0},{"id":"2484711677","title":"Madrigal Pharmaceuticals, Inc.涨4.07% 股价突破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2484711677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484711677?lang=zh_cn&edition=full","pubTime":"2024-11-18 23:53","pubTimestamp":1731945181,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日23时53分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价快速上涨4.07%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Hcw Biologics Inc.、Apollomics Inc C/Wts 01/04/2028 、冠科美博涨幅较大，Hcw Biologics Inc.、Tharimmune, Inc.、冠科美博较为活跃，换手率分别为726.77%、560.42%、448.40%，振幅较大的相关个股有Hcw Biologics Inc.、冠科美博、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为217.24%、75.18%、73.24%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111823530298e434c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111823530298e434c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","MDGL","BK4139"],"gpt_icon":0},{"id":"2483737734","title":"Madrigal Pharmaceuticals, Inc.跌0.88% 股价跌破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2483737734","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483737734?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:31","pubTimestamp":1731681077,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日22时31分，Madrigal Pharmaceuticals, Inc.股票出现异动，股价快速下跌0.88%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.69%。其相关个股中，Cero Therapeutics Holdings, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Tc Biopharm  Plc涨幅较大，Tc Biopharm  Plc、Elevai Labs, Inc.、Cero Therapeutics Holdings, Inc.较为活跃，换手率分别为2759.10%、160.65%、62.73%，振幅较大的相关个股有Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Cero Therapeutics Holdings, Inc.、Pulmatrix, Inc.，振幅分别为75.68%、42.74%、12.55%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115223117abc4e6a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115223117abc4e6a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDGL","BK4585","BK4588"],"gpt_icon":0},{"id":"2483831080","title":"Madrigal Pharmaceuticals, Inc.盘中异动 临近午盘急速跳水5.11%报321.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483831080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483831080?lang=zh_cn&edition=full","pubTime":"2024-11-14 00:57","pubTimestamp":1731517069,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日00时57分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速下挫5.11%。截至发稿，该股报321.72美元/股，成交量18.3607万股，换手率0.84%，振幅5.96%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，Nkgen Biotech Inc C/Wts 31/05/2028、Pulmatrix, Inc.、Calidi Biotherapeutics, Inc.涨幅较大，Cyclacel Pharmaceuticals, Inc.、Elevai Labs, Inc.、Calidi Biotherapeutics, Inc.较为活跃，换手率分别为492.38%、295.90%、116.28%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Calidi Biotherapeutics, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 ，振幅分别为101.00%、67.77%、52.94%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111400574998e426ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111400574998e426ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","MDGL","BK4588","BK4139"],"gpt_icon":0},{"id":"2482422487","title":"Madrigal Pharmaceuticals, Inc.2024财年第三财季实现净利润-1.07亿美元，同比减少8.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482422487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482422487?lang=zh_cn&edition=full","pubTime":"2024-11-10 00:01","pubTimestamp":1731168072,"startTime":"0","endTime":"0","summary":"11月10日，Madrigal Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比减少8.37%；其中营业收入为62.18百万美元，每股基本收益为-4.92美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.总负债2.96亿美元，其中短期债务878000.00美元，资产负债比为3.63，流动比率为5.98。机构评级：截至2024年11月10日，当前有15家机构对Madrigal Pharmaceuticals, Inc.目标价做出预测，其中目标均价为368.87美元，其中最低目标价为155.00美元，最高目标价为530.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL"],"gpt_icon":0},{"id":"2481139363","title":"Madrigal Pharmaceuticals, Inc.盘中异动 急速拉升5.40%报356.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481139363","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481139363?lang=zh_cn&edition=full","pubTime":"2024-11-08 01:25","pubTimestamp":1731000336,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日01时25分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.40%。截至发稿，该股报356.50美元/股，成交量18.0921万股，换手率0.83%，振幅4.96%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.94%。其相关个股中，Celularity Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为877.73%、416.82%、113.43%，振幅较大的相关个股有Celularity Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Ensysce Biosciences, Inc.，振幅分别为84.83%、68.89%、57.79%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108012536abaace44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108012536abaace44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDGL","BK4585","BK4588"],"gpt_icon":0},{"id":"1171768687","title":"异动解读 | 分析师上调目标价 Madrigal Pharmaceuticals盘中大涨5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171768687","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171768687?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:10","pubTimestamp":1730790651,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.股价在2024年11月4日盘中出现了5.54%的大幅上涨,引起了市场的广泛关注。\n\n根据公开的分析师报告,这一上涨可能与B. Riley分析师近期将该公司的目标价从194美元上调至236美元有关。分析师看好该公司的未来发展前景,上调目标价反映了对该公司业绩持乐观态度,这可能是推动股价上涨的主要原因之一。\n\n不过,也不能排除其他潜在的利好因素推动了该股的上涨,具体因素有待进一步观察和分析。投资者需要密切关注该公司的后续动态,以及分析师评级变化,以便及时做出投资决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"2481541559","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481541559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481541559?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","CI","NYT","EGHT","FIS","FOXA","OMI","ARES","RL","HIMS","GKOS","NMRA","ATUS","CSTL","LU0971096721.USD","INSP","SLAB","LU0320765489.SGD","MDGL","LU1489326972.SGD","BK4106","PTGX","LU0149725797.USD","BMRN","ILMN","LU1363072403.SGD","BWIN","KROS","AMG","LU0949170772.SGD","LU0266512127.USD","LU1244550221.USD","MAR","CMS","BEN","SHAK","LU","IE00BZ1G4Q59.USD","EVER","ST","CAMP","SM","RZLT","FRPT","AWI","EDIT","LSCC"],"gpt_icon":1},{"id":"2481415545","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481415545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481415545?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BWIN","EGHT","ILMN","NYT","RL","GKOS","BMRN","AWI","LU","LU1363072403.SGD","RZLT","IE00BZ1G4Q59.USD","IRON","MDGL","PTGX","CI","LU1489326972.SGD","AMG","LU0971096721.USD","BK4106","FOXA","NMRA","LU0149725797.USD","MAR","FIS","LU1244550221.USD","OMI","FRPT","INSP","EDIT","SHAK","BEN","LU0320765489.SGD","CAMP","SLAB","EVER","LSCC","SM","ATUS","LU0266512127.USD","ST","CSTL","CMS","LU0949170772.SGD","KROS","ARES"],"gpt_icon":1},{"id":"2481532292","title":"Madrigal Pharmaceuticals, Inc.盘中异动 下午盘大幅上涨5.00%报335.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481532292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481532292?lang=zh_cn&edition=full","pubTime":"2024-11-05 02:02","pubTimestamp":1730743378,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日02时02分，Madrigal Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.00%。截至发稿，该股报335.55美元/股，成交量56.0687万股，换手率2.57%，振幅7.82%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Neurogene Inc.、Tenaya Therapeutics, Inc.、Disc Medicine, Inc.涨幅较大，Elevai Labs, Inc.、Nls Pharmaceutics Ltd.、Tc Biopharm  Plc较为活跃，换手率分别为398.35%、281.92%、83.72%，振幅较大的相关个股有Sab Biotherapeutics Inc C/Wts 22/10/2026 、In8Bio, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 ，振幅分别为52.25%、45.39%、43.11%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105020259a215a36c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105020259a215a36c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"1182951687","title":"异动解读 | Madrigal新药Rezdiffra大卖 引爆公司股价大涨23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182951687","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182951687?lang=zh_cn&edition=full","pubTime":"2024-11-02 06:34","pubTimestamp":1730500472,"startTime":"0","endTime":"0","summary":"生物制药公司Madrigal Pharmaceuticals Inc.今日股价盘中大涨23.39%,引发市场高度关注。引发这一走势的直接原因是该公司旗舰新药Rezdiffra在2024年第三季度的销售表现远超预期。Rezdiffra强劲的销售业绩不断增强了投资者对该公司长期增长潜力的信心,从而推动了当天股价的大涨表现。随着NASH认知度的不断提高,未来Rezdiffra销量有望持续攀升,市场预期Madrigal将成为该潜力无限的新兴疾病领域的龙头企业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"1134417751","title":"异动解读 | NASH新药Rezdiffra大热 Madrigal股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1134417751","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134417751?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:33","pubTimestamp":1730468016,"startTime":"0","endTime":"0","summary":"美国生物制药公司Madrigal Pharmaceuticals Inc.今日盘中股价大涨5.97%,引发市场高度关注。引发这一走势的主要原因是该公司旗舰新药Rezdiffra在2024年第三季度销售表现远超预期。Rezdiffra的上市填补了这一空白,其出色的销售业绩反映了广大患者对这一创新药物的巨大需求。随着NASH认知度的不断提高,未来Rezdiffra销量有望持续攀升,市场预期Madrigal将成为该潜力无限的新兴疾病领域的龙头企业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"1123656017","title":"异动解读 | NASH新药Rezdiffra销量大热 MDGL股价盘前大涨5.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123656017","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123656017?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:30","pubTimestamp":1730467852,"startTime":"0","endTime":"0","summary":"生物制药公司Madrigal Pharmaceuticals Inc.今日股价盘前大涨5.9%,主因在于该公司新上市药品Rezdiffra在2024年第三季度取得了远超市场预期的出色销售业绩。Rezdiffra是全球首款获FDA批准治疗NASH的药物。Rezdiffra强劲的执行表现已经加强了投资者对MDGL公司长期增长潜力的信心,推动了今日股价的大涨。随着公众对NASH认知度的不断提升,未来Rezdiffra销售有望持续攀升,使MDGL被寄予厚望成为这一潜力无限的新兴疾病领域的龙头企业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"2480588999","title":"Madrigal Pharmaceuticals, Inc.盘中异动 快速拉升6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480588999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480588999?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:30","pubTimestamp":1730467833,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日21时30分，Madrigal Pharmaceuticals, Inc.股票出现异动，股价快速上涨6.03%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Theriva Biologics, Inc.、Genelux Corporation涨幅较大，Theriva Biologics, Inc.、Athira Pharma, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为1114.49%、92.50%、72.07%，振幅较大的相关个股有Theriva Biologics, Inc.、Madrigal Pharmaceuticals, Inc.、Mesoblast Ltd，振幅分别为5.47%、3.84%、3.40%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213033a20943c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213033a20943c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","MDGL","BK4585","BK4139"],"gpt_icon":0},{"id":"2480396378","title":"更新版 4-重发-诺和诺德减肥药试验显示脂肪肝病情有所改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2480396378","media":"路透中文","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480396378?lang=zh_cn&edition=full","pubTime":"2024-11-01 20:42","pubTimestamp":1730464955,"startTime":"0","endTime":"0","summary":"更新版 4-重发-诺和诺德减肥药试验显示脂肪肝病情有所改善第 8 段添加了分析师评论，第 9 段添加了其他制药商的股票走势Sriparna  Roy. 路透11月1日 - 诺和诺德NOVOb.CO周五表示，其减肥药物在一种脂肪肝患者的后期试验中达到了主要目标，即在不恶化病情的情况下减少了器官的瘢痕。诺和诺德公司预计将于 2025 年上半年在美国和欧盟申请监管批准。诺和诺德与礼来公司还在测试他们的减肥药对其他几种疾病的疗效 ，包括阿尔茨海默病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nL4S3M81EZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203202063.USD","LU0417517546.SGD","IE0002141913.USD","LU0097036916.USD","LU1093756168.USD","IE00B1BXHZ80.USD","LU0354030438.USD","MDGL","LU0238689110.USD","BK4139","LU0122379950.USD","LU1057294990.SGD","LU0114720955.EUR","LU0456855351.SGD","IE0004445239.USD","LU0820561818.USD","LU0079474960.USD","LU0823416689.USD","IE00BJLML261.HKD","BK4505","LU1035775433.USD","LU0689472784.USD","BK4533","AKRO","LU0471298694.HKD","IE00BK4W5L77.USD","LU0203201768.USD","LU0094547139.USD","LU0820561909.HKD","LU0061475181.USD","LU0058720904.USD","LU0882574139.USD","GB00BDT5M118.USD","BK4534","LU1061106388.HKD","LU0198837287.USD","LU0256863811.USD","IE00B2B36J28.USD","BK4581","LU0471298777.SGD","IE00BK4W5M84.HKD","LU0006306889.USD","LU0640476718.USD","IE00BJT1NW94.SGD","BK4007","BK4588","LU0096364046.USD","BK4585","LU0354030511.USD","LLY"],"gpt_icon":1},{"id":"1101493926","title":"异动解读 | NASH新药Rezdiffra出色销售 助MDGL股价盘中大涨21.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101493926","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101493926?lang=zh_cn&edition=full","pubTime":"2024-11-01 11:56","pubTimestamp":1730433398,"startTime":"0","endTime":"0","summary":"美国生物制药公司Madrigal Pharmaceuticals Inc.今日盘中股价大涨21.85%,引发市场高度关注。引发这一疯涨的主要原因是该公司旗舰药品Rezdiffra在2024年第三季度销售表现远超预期。Rezdiffra出色的执行表现不断增强着投资者对该公司长期增长潜力的信心,这也是今日股价大涨的主因。随着NASH疾病认知度的不断提高,未来Rezdiffra销售有望持续攀升,Madrigal公司也被寄予厚望成为这一细分市场的领跑者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"1165049126","title":"异动解读 | MDGL旗舰药品飙红 第三季度销售大胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165049126","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165049126?lang=zh_cn&edition=full","pubTime":"2024-11-01 02:20","pubTimestamp":1730398840,"startTime":"0","endTime":"0","summary":"美国生物制药公司Madrigal Pharmaceuticals Inc.今日盘中大涨18.28%,股价一度触及253.55美元。引发这一疯涨的主要原因是该公司旗舰药品Rezdiffra在上一季度的出色表现。数据显示,Rezdiffra在2024年第三季度实现销售额6220万美元,远超市场预期的3420万美元。作为全球首款获FDA批准的NASH治疗药物,这已是Rezdiffra连续第二个季度取得强劲上市表现,进一步增强了投资者对该药物潜在用药人群需求的信心。Rezdiffra出色的销售业绩持续提振着投资者的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"1126617318","title":"异动解读 | 首款NASH治疗药物销售出色 Madrigal Pharmaceuticals盘前大涨17.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126617318","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126617318?lang=zh_cn&edition=full","pubTime":"2024-11-01 00:24","pubTimestamp":1730391882,"startTime":"0","endTime":"0","summary":"美国生物制药公司Madrigal Pharmaceuticals, Inc.在2024年10月31日盘前大涨17.4%,股价一度触及253.55美元,创下近两个月新高。这主要得益于该公司旗舰药品Rezdiffra在上一季度表现亮眼。Rezdiffra是首个获得美国FDA批准的NASH治疗药物。这是Rezdiffra连续第二个季度取得强劲上市执行,进一步增强了市场对其潜在患者/用药者需求的信心。分析人士表示,作为NASH领域的先行者,Madrigal公司有望利用其先发优势和商业经验来抓住这一新兴市场的机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"gpt_icon":0},{"id":"2480053625","title":"BUZZ-脂肪肝药物第三季度销售额超出预期，Madrigal 公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2480053625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480053625?lang=zh_cn&edition=full","pubTime":"2024-11-01 00:19","pubTimestamp":1730391542,"startTime":"0","endTime":"0","summary":"    10月31日 - ** Madrigal Pharmaceuticals   股价上涨多达 17.4%，达到两个月来的最高点 253.55 美元** 如果涨势保持，股价将创下自2022年12月以来的最佳表现** 该公司第三季度唯一的产品--脂肪肝药物Rezdiffra的利润为6220万美元，超过华尔街预期的3420万美元 - LSEG** 脂肪肝被称为代谢功能障碍相关性脂肪性肝炎，约占美国人口的 5%。这种疾病早先被称为非酒精性脂肪性肝炎。** MDGL 能够成功利用其先行者优势和商业经验来创造 NASH 市场机会 - Leerink** 今年 3 月，Rezdiffra 成为首个获得美国 FDA 批准的 NASH 药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","MDGL","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0878},{"period":"1month","weight":0.6172},{"period":"3month","weight":0.3027},{"period":"6month","weight":0.4341},{"period":"1year","weight":0.7285},{"period":"ytd","weight":0.4229}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Madrigal Pharmaceuticals, Inc.于2000年3月成立并在2001年7月开始运营。 Synta制药公司是一家生物制药公司，致力于发现、开发和商业化小分子药物以扩大和加强带有严重疾病的患者的生命，包括癌症和慢性症性疾病。该公司有两种候选药物在临床实验中用于治疗多种类型的癌症和几个用于临床前研究阶段的候选药物。所有公司的候选药物利用公司的专利、独特的化合物和集成的发现引擎发现。这家公司保留了其候选药物的全部选择权。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032263},{"month":2,"riseRate":0.75,"avgChangeRate":0.088162},{"month":3,"riseRate":0.25,"avgChangeRate":-0.038862},{"month":4,"riseRate":0.5,"avgChangeRate":0.008688},{"month":5,"riseRate":0.375,"avgChangeRate":0.168822},{"month":6,"riseRate":0.625,"avgChangeRate":0.024173},{"month":7,"riseRate":0.125,"avgChangeRate":-0.088753},{"month":8,"riseRate":0.555556,"avgChangeRate":0.058165},{"month":9,"riseRate":0.333333,"avgChangeRate":0.13282},{"month":10,"riseRate":0.666667,"avgChangeRate":0.070394},{"month":11,"riseRate":0.555556,"avgChangeRate":0.063258},{"month":12,"riseRate":0.5,"avgChangeRate":0.475789}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals, Inc.","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Madrigal Pharmaceuticals, Inc.,MDGL,Madrigal Pharmaceuticals, Inc.股票,Madrigal Pharmaceuticals, Inc.股票老虎,Madrigal Pharmaceuticals, Inc.股票老虎国际,Madrigal Pharmaceuticals, Inc.行情,Madrigal Pharmaceuticals, Inc.股票行情,Madrigal Pharmaceuticals, Inc.股价,Madrigal Pharmaceuticals, Inc.股市,Madrigal Pharmaceuticals, Inc.股票价格,Madrigal Pharmaceuticals, Inc.股票交易,Madrigal Pharmaceuticals, Inc.股票购买,Madrigal Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}